What Is Dacarbazine?
The chemical name of this product is: 5- (3,3-dimethyl-1-triazenyl) -4-amidoimidazole citrate. Alias, amenomidamine. Decomposition of this product in the body can release methyl cation (CH3) +, play an alkylation role; at the same time, this product can become a substance similar to the intermediates of purine biosynthesis, which may interfere with the biosynthesis of purines. This product is not completely absorbed orally, and individual differences are large, so all intravenous injection. Because the blood-brain barrier cannot be penetrated, brain metastases can still occur when effective on the primary tumor.
Dacarbazine
- [English name] Dacarbazine
- [Other names] dacarbazine citrate, dacarbazine, aminobenzimidamine, azolidamine, dacarbazine citrate, azamidazine citrate, azamidazine, methazine , Caldaba anti-melanoma, anti-melanin, trichloroene imidazolium, triazine imidazole, triazine imidazolium, Biocarbazine-R, Da-c
- [Indications] Suitable for melanoma, soft tissue tumor, malignant lymphoma, etc.
- [Drug Category] Antitumor Drugs-Other Antitumor Drugs and Cancer Auxiliary Drugs-Dacarbazine
- [Ingredients] dacarbazine. Chemical name: 5- (3,3-dimethyl-1-triazene) -imidazole-4-carboxamide citrate.
- [Character] This product is a kind of white or reddish loose bulk or powder.
- English alias: 5- (3,3-Dimethyl-1-triazenyl) imidazole-4-carboxamide; 4- (3,3-Dimethyltriazeno) imidazole-5-carboxamide; 4- (Dimethyltriazeno) imidazole-5-carboxamide
- CAS number: 4342-03-4
- Molecular formula: C6H10N6O
- Molecular weight: 182.18
- Structural formula:
- [Storage] Keep sealed and protected from light below 5 ° C.
- S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
- After accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.
- S36 Wear suitable protective clothing.
- Wear appropriate protective clothing.
- S45 In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
- In case of accident or if you feel unwell, seek medical advice immediately (show the label if possible).
- S53 Avoid exposure-obtain special instructions before use.
- Avoid contact. Obtain special instructions before use.
- S36 / 37/39 Wear suitable protective clothing, gloves and eye / face protection.
- Wear appropriate protective clothing, gloves and goggles or masks.
- S37 / 39 Wear suitable gloves and eye / face protection
- Wear appropriate gloves and goggles or a mask.
- R45 May cause cancer.
- May cause cancer.
- R46 May cause heritable genetic damage.
- May cause hereditary genetic damage.
- R20 / 21/22 Harmful by inhalation, in contact with skin and if swallowed.
- Harmful by inhalation, in contact with skin and if swallowed.
- R36 / 37/38 Irritating to eyes, respiratory system and skin.
- Irritation of eyes, respiratory system and skin.
- [Dosing Instructions]
- 1. If it leaks out of the blood vessel during intravenous injection, the injection should be stopped immediately and sealed with 1% procaine injection.
- 2. Oral polio vaccine should be avoided during medication.
- [Usage and dosage]
- 1. Intravenous injection: 200 ~ 400mg once, for 3 to 5 days, dissolve intravenously with sodium chloride injection, or iv drip 250ml of 5% glucose injection.
- 2. Combined chemotherapy: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), mainly used for Hodgkin's lymphoma; CY-VA-DIC (cyclophosphamide, vinblastine, doxorubicin) Bixin and dacarbazine) are mainly used in soft tissue sarcomas.
- [Formulations and specifications] dacarbazine citrate for injection: 200mg.
- [Drug interaction] When this product is used in combination with other drugs that inhibit bone marrow or radiation, the dose of this product should be reduced.
- [Pharmacokinetics] The plasma concentration reached the highest peak 30 minutes after an intravenous injection. Plasma disappeared in a two-compartment model with t1 / 2a of 19 minutes and t1 / 2B of 5 hours. Within 0 to 6 hours, 45% is excreted from the urine (50% is the original drug and 50% is the metabolite). Can't cross the blood-brain barrier.
- [Pharmacology and Toxicology]
- 1.Pharmacology
- 1. Breastfeeding should be stopped during medication.
- Store
- 3. Live virus vaccination is prohibited during medication.
- 4. Use this product with caution in patients with liver and kidney damage and infection.
- 5. Blood urea nitrogen, creatinine, uric acid, serum bilirubin, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase should be regularly checked during the medication.
- 6 Because this product is extremely unstable to light and heat, it is prone to red when exposed to light or heat, unstable in water, and the solution becomes light red after standing. It should be prepared temporarily and injected immediately after dissolution. And try to avoid light.
- 7 The intravenous drip rate should not be too fast.
- 8 Prevent leakage of drugs and avoid local tissue irritation.